← Leaderboards
Scott W Woods
Yale University
$46,801,415
Attributed
$119,352,024
Total exposure
11
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $27.2M · FY2005–25$50M$37.5M$25M$12.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$118,852,220 · 9
FDA$499,804 · 2
By mechanism
U01$112,579,732 · 6
R01$6,035,281 · 4
R41$737,011 · 1
Top collaborators
- Carrie E Bearden16 shared
- John M Kane16 shared
- Philip Corlett9 shared
- Youngsun T Cho2 shared
- Catalina Valerie Mourgues-Codern2 shared
- Albert R Powers1 shared
Most similar at Yale University
Same institution · by research overlap
- Kristen Jennifer Brennand$23,065,666
- R. Todd Constable$27,324,295
- Dustin Scheinost$8,044,506
- Albert R Powers$12,336,008
- Meenakshi Alreja$2,438,822
Others in their field
Top investigators on “Site”
- Lawrence Corey · Fred Hutchinson Cancer Center$727,416,881
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$630,131,001
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
SitePsychotic DisordersHigh RiskNeurobiologySchizophreniaPreventBiological MarkersSymptomsBehavioralSyndromeStructureFollow-UpCollaborationsAffectSamplingDesignBrainInterestLinkBaseProgramsPsychopathologyParticipantRecruit
Grant awards (61)
ProCAN: Psychosis Risk Outcomes Compound Assessment Network$16,589,886
U01 · FY2025 · MH · contact PI
ProNET: Psychosis-Risk Outcomes Network$8,966,694
U01 · FY2025 · MH · contact PI
DDT-COA-000-163 Accelerating the FDA COA Qualification Package for thePSYCHS as a ClinRO measure$250,000
U01 · FY2025 · FD
ProNET: Psychosis-Risk Outcomes Network$194,998
U01 · FY2025 · MH · contact PI
ProNET: Psychosis-Risk Outcomes Network$184,327
U01 · FY2025 · MH · contact PI
ProNET: Psychosis-Risk Outcomes Network$182,188
U01 · FY2025 · MH · contact PI
ProNET: Psychosis-Risk Outcomes Network$182,145
U01 · FY2025 · MH · contact PI
ProNET: Psychosis-Risk Outcomes Network$180,329
U01 · FY2025 · MH · contact PI
ProNET: Psychosis-Risk Outcomes Network$170,625
U01 · FY2025 · MH · contact PI
ProNET: Psychosis-Risk Outcomes Network$148,057
U01 · FY2025 · MH · contact PI
ProNET: Psychosis-Risk Outcomes Network$136,841
U01 · FY2025 · MH · contact PI
ProCAN: Psychosis Risk Outcomes Compound Assessment Network$14,993,866
U01 · FY2024 · MH · contact PI
ProNET: Psychosis-Risk Outcomes Network$9,344,586
U01 · FY2024 · MH · contact PI
5/5 CAPER: Computerized Assessment of Psychosis Risk$585,117
R01 · FY2024 · MH
5/5 CAPER: Computerized Assessment of Psychosis Risk$49,883
R01 · FY2024 · MH
ProNET: Psychosis-Risk Outcomes Network$11,636,305
U01 · FY2023 · MH · contact PI
5/5 CAPER: Computerized Assessment of Psychosis Risk$585,117
R01 · FY2023 · MH
DDT-COA-000-163 Accelerating the FDA COA Qualification Plan for the PSYCHS as a ClinRO measure$249,804
U01 · FY2023 · FD
5/5 CAPER: Computerized Assessment of Psychosis Risk$59,859
R01 · FY2023 · MH
ProNET: Psychosis-Risk Outcomes Network$15,918,096
U01 · FY2022 · MH · contact PI
5/5 CAPER: Computerized Assessment of Psychosis Risk$585,117
R01 · FY2022 · MH
5/5 CAPER: Computerized Assessment of Psychosis Risk$59,859
R01 · FY2022 · MH
5/5 CAPER: Computerized Assessment of Psychosis Risk$9,976
R01 · FY2022 · MH
ProNET: Psychosis-Risk Outcomes Network$12,623,656
U01 · FY2021 · MH · contact PI
ProNET: Psychosis-Risk Outcomes Network$2,115,894
U01 · FY2021 · MH · contact PI
5/5 CAPER: Computerized Assessment of Psychosis Risk$579,032
R01 · FY2021 · MH
ProNET: Psychosis-Risk Outcomes Network$10,861,093
U01 · FY2020 · MH · contact PI
5/5 CAPER: Computerized Assessment of Psychosis Risk$572,946
R01 · FY2020 · MH
8/9 Predictors and Mechanisms of Conversion to Psychosis$313,233
U01 · FY2018 · MH · contact PI
8/9 Predictors and Mechanisms of Conversion to Psychosis$381,506
U01 · FY2017 · MH · contact PI
8/9 Predictors and Mechanisms of Conversion to Psychosis$611,035
U01 · FY2016 · MH · contact PI
8/9 Predictors and Mechanisms of Conversion to Psychosis$558,074
U01 · FY2015 · MH · contact PI
8/9 Predictors and Mechanisms of Conversion to Psychosis$69,280
U01 · FY2015 · MH · contact PI
8/9 Predictors and Mechanisms of Conversion to Psychosis$538,617
U01 · FY2014 · MH · contact PI
8/8-Predictors and Mechanisms of Conversion to Psychosis$208,949
U01 · FY2014 · MH · contact PI
8/8-Predictors and Mechanisms of Conversion to Psychosis$150,853
U01 · FY2013 · MH · contact PI
8/8-Predictors and Mechanisms of Conversion to Psychosis$630,893
U01 · FY2012 · MH · contact PI
8/8-Predictors and Mechanisms of Conversion to Psychosis$649,128
U01 · FY2011 · MH · contact PI
8/8-Predictors and Mechanisms of Conversion to Psychosis$77,316
U01 · FY2011 · MH · contact PI
8/8-Predictors and Mechanisms of Conversion to Psychosis$661,684
U01 · FY2010 · MH · contact PI
Huperzine for Cognitive and Functional Impairment in Schizophrenia$240,989
R41 · FY2010 · MH · contact PI
8/8-Predictors and Mechanisms of Conversion to Psychosis$592,968
U01 · FY2009 · MH · contact PI
Huperzine for Cognitive and Functional Impairment in Schizophrenia$246,022
R41 · FY2009 · MH · contact PI
Huperzine for Cognitive and Functional Impairment in Schizophrenia$34,149
R41 · FY2009 · MH · contact PI
8/8-Predictors and Mechanisms of Conversion to Psychosis$579,595
U01 · FY2008 · MH · contact PI
Huperzine for Cognitive and Functional Impairment in Schizophrenia$215,851
R41 · FY2008 · MH · contact PI
Enhancing the Prospective Prediction of Psychosis$310,411
U01 · FY2007 · MH · contact PI
Enhancing the Prospective Prediction of Psychosis$319,682
U01 · FY2006 · MH · contact PI
Enhancing the Prospective Prediction of Psychosis$322,825
U01 · FY2005 · MH
Enhancing the Prospective Prediction of Psychosis$356,263
U01 · FY2004 · MH
TARDIVE DYSKINESIA INCIDENCE AND ATYPICAL ANTIPSYCHOTIC$248,574
R01 · FY2004 · MH
TARDIVE DYSKINESIA INCIDENCE AND ATYPICAL ANTIPSYCHOTIC$323,003
R01 · FY2003 · MH
Enhancing the Prospective Prediction of Psychosis$318,030
U01 · FY2003 · MH
TREATMENT OF PANIC DISORDER--LONG TERM STRATEGIES$250,483
R01 · FY2003 · MH
TARDIVE DYSKINESIA INCIDENCE AND ATYPICAL ANTIPSYCHOTIC$323,788
R01 · FY2002 · MH
TREATMENT OF PANIC DISORDER--LONG TERM STRATEGIES$261,148
R01 · FY2002 · MH
TARDIVE DYSKINESIA INCIDENCE AND ATYPICAL ANTIPSYCHOTIC$309,570
R01 · FY2001 · MH
TREATMENT OF PANIC DISORDER--LONG TERM STRATEGIES$295,202
R01 · FY2001 · MH
TARDIVE DYSKINESIA INCIDENCE AND ATYPICAL ANTIPSYCHOTICS$403,777
R01 · FY2000 · MH
TREATMENT OF PANIC DISORDER--LONG TERM STRATEGIES$279,646
R01 · FY2000 · MH
ATYPICAL ANTIPSYCHOTIC MEDICATIONS--OUTCOMES AND COSTS$253,184
R01 · FY2000 · MH